A Study Evaluating the Long-term Safety and Efficacy of Vx-659 Combination Therapy

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects with Cystic Fibrosis who are Homozygous or Heterozygous for the F508del Mutation

Key Eligibility Criteria

Confirmed diagnosis of Cystic Fibrosis

Carry genotype as selected by protocol

FEV1 range >40% – 90%

Age 12 years and older

Therapeutic Area

Cystic Fibrosis

Type of Study

Phase III Clinical Trial

Study Status

Open Recruiting

Sponsor

Vertex Pharmaceuticals

Principal Investigator

Professor Edward McKone

Contact

brenda.grogan@ucd.ie